Presentation at the 32nd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID)
Crestone presents at the 32nd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) in Lisbon, Portugal. Oral Session: Discovery of CRS0393, a Potent MmpL3 Inhibitor as a Novel Antimycobacterial Agent.
Crestone, Inc. joins the Antimicrobials Working Group to Combat Drug Resistant Infections
June 8, 2021. The Antimicrobials Working Group (AWG) announced today the addition of Crestone, Inc. to its coalition of companies with the mission to combat drug resistant infections and spur life-saving innovations. Learn More:...
CFF Funding Secured for Preclinical Development of Novel Antibiotic to Treat NTM Infections
Crestone, Inc. (Boulder) Secures CFF Funding for Preclinical Development of Novel Antibiotic to Treat NTM Infections. Learn More: https://www.businesswire.com/news/home/20200113005023/en/Crestone-Boulder-Secures-CFF-Funding-Preclinical-Development